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bNational Yang-Ming University, Taipei, Taiwan.
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BACKGROUND/PURPOSE: Reports detailing bacteremia caused by Chryseobacterium indologenes remain 
limited, with most cases reported in Taiwan. The clinical significance of C. indologenes has not been fully 
established. This retrospective study investigated the clinical features and antimicrobial susceptibility of 
C. indologenes bacteremia.
METHODS: Patients with C. indologenes bacteremia were identified at a medical center/teaching hospital 
in northern Taiwan between January 1, 2004 and January 31, 2008. Clinical features and the antimicrobial 
susceptibilities of these patients were analyzed.
RESULTS: Sixteen isolates of C. indologenes from 16 episodes in 16 patients were identified, with all patients 
having underlying diseases. Two patients (12.5%) had polymicrobial bacteremia. The portal of bacteremia 
was not determined in most cases. Other clinical syndromes included catheter-related bacteremia, urinary 
tract infection and peritonitis. The majority of patients had undergone invasive procedures. Other associated 
conditions included immunosuppression, neutropenia and prolonged use of antibiotics. Only three pa-
tients were treated with appropriate antibiotics according to minimum inhibitory concentrations. The 
susceptibilities of isolates to trimethoprim-sulfamethoxazole (75.0%), levofloxacin (62.5%), piperacillin-
tazobactam (50.0%), ciprofloxacin (43.75%) and cefepime (12.5%) were variable and the bacteremia-related 
mortality rate was 6.25%.
CONCLUSION: C. indologenes isolates are resistant to multiple antibiotics, with newer fluoroquinolones 
and trimethoprim-sulfamethoxazole possibly representing the most appropriate antimicrobial agents 
to treat infections caused by this pathogen. However, the pathogenicity and factors of virulence for 
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Introduction
Chryseobacterium species are a group of non-motile, cata-
lase-positive, oxidase-positive, indole-positive and non-
glucose-fermenting Gram-negative bacilli. The genus 
Chryseobacterium includes six species that were previously 
designated as members of the genus Flavobacterium.1 
C. gleum and C. indologenes, formerly known as Flavobacterium 
CDC group IIb, have been clearly differentiated by DNA–
DNA homology and eight phenotypic characteristics.2 
C. meningosepticum and C. indologenes are two species com-
monly isolated from clinical specimens with C. meningosep-
ticum the most pathogenic member of the genus. However, 
the clinical significance of C. indologenes has not been fully 
established because this bacterium is not frequently re-
covered from clinical specimens. C. indologenes is a rare path-
ogen in humans and is not normally present in the human 
microflora although it is widely distributed in nature.3 To 
the best of our knowledge, there are only 42 reported cases 
of C. indologenes bacteremia in the literature, with most 
cases reported in Taiwan.3–12
In this study, we analyzed 16 patients with C. indolo-
genes bacteremia in our institute over a 4-year period. We 
highlighted the clinical features of C. indologenes bacter-
emia as well as the antimicrobial susceptibility pattern of 
this pathogen.
Methods
Patient identification
Patients with C. indologenes bacteremia were identified 
retrospectively from blood culture reports, from the clini-
cal microbiology laboratory at Taipei Veterans General 
Hospital (TVGH) between January 1, 2004 and January 
31, 2008. The TVGH is a medical center and teaching 
hospital with a capacity of 2,900 beds in northern Taiwan. 
All medical records of patients whose blood cultures posi-
tive for C. indologenes were reviewed retrospectively. Patients 
younger than 18 years of age were excluded. There was no 
apparent outbreak of C. indologenes infection during the 
time of our study.
Definitions
An episode of significant bacteremia was defined as one 
or more blood cultures positive for C. indologenes together 
with clinical sepsis. Bacteremia without clinical sepsis was 
considered contamination and was excluded. Nosocomial 
bacteremia was defined as bacteremia occurring ≥ 48 hours 
after admission, or bacteremia for which the patient had 
been hospitalized at any time within the previous month. 
Central venous catheter (CVC)-related bacteremia was re-
corded when C. indologenes was isolated simultaneously 
from blood and either the tip of the catheter or purulent 
discharge from the CVC site, or there was a positive blood 
culture for C. indologenes with the presence of inflammation 
at the CVC site without another identifiable source of in-
fection. Prolonged antibiotic use defined as administration 
of intravenous antibiotics for more than 14 days within a 
30-day period prior to the diagnosis of bacteremia. Immu-
nosuppressive therapy was defined as the use of cytotoxic 
agents or corticosteroids (> 30 mg prednisolone daily or 
equivalent for ≥ 1 week). Neutropenia defined as an abso-
lute neutrophil count less than 500/μL. Recent surgery 
defined as a surgical procedure performed within 1 month 
prior to the onset of C. indologenes bacteremia. Appropriate 
antibiotic therapy defined as the use of at least one intra-
venous antibiotic to which the microorganism was sus-
ceptible according to minimum inhibitory concentration 
(MIC) testing within 72 hours of the diagnosis of bacter-
emia. Death was considered to have been related to bac-
teremia if the patient died ≤ 14 days after the onset of 
bacteremia and if no other cause of death was identified.
C. indologenes remain unclear, with our study revealing favorable outcomes of C. indologenes bacteremia. 
Epidemiological surveillance of this organism in Taiwan and extensive worldwide surveillance programs 
are required.
KEYWORDS: antibacterial agents, bacteremia, Chryseobacterium indologenes
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Blood culture samples were processed using the BACTEC 
NR-660 instrument (Becton Dickinson, Sparks, MD, USA). 
All positive cultures were examined following Gram stain-
ing and were subcultured on blood agar plates and eosin-
methylene blue agar plates for further identification. All 
isolates were oxidase-positive Gram-negative rods that did 
not ferment glucose. The ID32 GN system (bioMérieux, 
Marcy l’Etoile, France) was used for identifying C. indolo-
genes. All blood culture isolates were stored at –70°C and 
these frozen stocks were subcultured twice before further 
confirmation. The VITEK 2 system (bioMérieux) with a 
VITEK 2 GN card was used to confirm bacterial identifi-
cation according to the manufacturer’s instructions.
The MIC values for bacteremic isolates of C. indologenes 
were performed using the VITEK 2 system with an AST 
GN-09 card following the manufacturer’s instructions. 
The breakpoints of MICs for susceptibility were deter-
mined by applying the Clinical and Laboratory Standards 
Institute (CLSI) standards for susceptibility for Pseudomonas 
aeruginosa and non-Enterobacteriaceae.13
Results
Bacterial isolates
Sixteen isolates of C. indologenes were initially identified by 
the ID32 GN system during the study period. The VITEK 
2 system with a VITEK 2 GN card was used to confirm the 
identity of bacteria. All 16 microorganisms were identified 
as C. indologenes.
Clinical characteristics
Sixteen significant episodes of C. indologenes bacteremia in 
16 patients were identified during the study period. The 
clinical characteristics of the 16 patients with C. indologenes 
bacteremia are summarized in Tables 1 and 2. Male patients 
predominated (75%), and the mean age of affected patients 
was 66 years (range, 44–86 years), with seven patients older 
than 80 years.
Underlying diseases were present in all patients and 
all bacteremic episodes were nosocomial. Two patients 
(12.5%) had polymicrobial bacteremia and C. indologenes 
was also isolated simultaneously from other sites in two 
patients. Of the 16 patients, 13 patients had associated 
conditions, including central venous catheterization (n = 7), 
indwelling urinary catheter (n = 7), immunosuppression 
(n = 5), prolonged antibiotics use (n = 5), ventilator use 
(n = 3), neutropenia (n = 3), recent surgery (n = 2), intensive 
care unit admission (n = 2), total parenteral nutrition 
(n = 1), percutaneous nephrostomy (n = 1) and jejuno-
stomy (n = 1). The most common clinical manifestation was 
primary bacteremia. In addition to the 12 patients with 
primary bacteremia, two patients had catheter-related 
bacteremia and one patient had urinary tract infection 
and peritonitis.
Three patients (18.8%) were treated with antibiotics 
appropriate to the MIC test results; their condition im-
proved within 5 days of the initiation of treatment. Of 
the 13 patients not treated with appropriate antibiotics, 
10 patients improved within 7 days of the initiation of 
antibiotics. The CVC was removed from the two patients 
not treated with appropriate antibiotics for catheter-
related bacteremia. Two patients died within 14 days after 
the onset of bacteremia. One patient (patient 13) died of 
acute myocardial infarction on the second day of admis-
sion; therefore, the clinical response to antibiotics could 
not be determined. Only one patient (6.3%) not treated 
with appropriate antibiotics fulfilled the definition of 
bacteremia-related mortality. Bacteremia occurred on the 
58th day of hospitalization and he received antibiotics for 
a prolonged period before the onset of bacteremia. Sepsis 
progressed despite treatment with cefepime and he died 
on the 12th day after bacteremia onset.
Antimicrobial susceptibility
The results of susceptibility testing with antimicrobial 
agents are shown in Table 3. Our isolates were susceptible 
to trimethoprim-sulfamethoxazole (75.0%), levofloxacin 
(62.5%), ciprofloxacin (43.8%), piperacillin-tazobactam 
(50.0%) and cefepime (12.5%), but at various levels. All 
isolates were resistant to other β-lactam antibiotics and 
aminoglycosides.
Discussion
C. indologenes is widely distributed in nature but is a rare 
human pathogen. It has been isolated from clinical speci-
mens but rarely from blood3 and has been shown to cause 
a variety of invasive infections, such as primary bacter-
emia, catheter-related bacteremia, wound sepsis, cellulitis, 
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Table 2. Treatment and outcomes of 16 patients with bacteremia caused by Chryseobacterium indologenesa
Case
 
Antibiotic treatment
 Appropriate Clinical 
Outcome
 Day of
  antibiotic use response  mortalityb
 1 Ciprofloxacin Yes Improved Died of other causes Day 58
 2 Piperacillin-tazobactam plus amikacin No Improved Survival –
 3 Oral cefadroxil associated removal of CVC No Improved Survival –
 4 Cefepime No Failure Bacteremia-related mortality Day 12
 5 Piperacillin-tazobactam No Improved Survival –
 6 Ciprofloxacin No Failure Died of other causes Day 28
 7 Amoxicillin-clavulanate plus isepamicin No Improved Survival –
 8 Cefepime + fosfomycin Yes Improved Died of other causes Day 21
 9 Ceftazidime associated removal of CVC No Improved Died of other causes Day 52
10 Ceftazidime + isepamicin No Improved Survival –
11 Amoxicillin-clavulanate No Improved Survival –
12 Amoxicillin-clavulanate No Improved Survival –
13 Ceftriaxone No Indeterminate Died of other causes Day 2
14 Cefuroxime No Improved Survival –
15 Ciprofloxacin Yes Improved Survival –
16 Ceftazidime No Improved Survival –
aInfections were nosocomial in all patients. Patient 2 was discharged from oncology department 1 week earlier; Patient 13 was transferred 
from a local medical department where she had been hospitalized for 17 days prior to admission to our hospital. Bacteremia occurred in dif-
ferent wards of the oncology department. Patients 1 and 6 died of ventilator-associated pneumonia. Patients 8 and 9 were in the terminal 
stages of underlying malignancy and subsequently died. Patient 13 died of acute myocardial infarction; bday of mortality after onset of bacter-
emia. CVC = central venous catheter.
Table 3. Antimicrobial spectrum of selected antimicrobial agents against Chryseobacterium indologenes
Antimicrobial agent
 MIC range MIC50 MIC90 Susceptibility No of isolates
 (μg/mL) (μg/mL) (μg/mL) breakpoint (μg/mL) susceptiblea
Ciprofloxacin 1 to ≥ 4 2  ≥ 4 ≤ 1 7 (43.75)
Levofloxacin 1 to ≥ 8 1  ≥ 8 ≤ 2 10 (62.5)
Piperacillin 64 to ≥ 128 ≥ 128 ≥ 128 ≤ 16 0 (0)
Piperacillin-tazobactam ≤ 4 to ≥ 128 16 ≥ 128 ≤ 16 8 (50.0)
TMP-SMZ ≤ 1/19 to ≥ 16/304 2/38 ≥ 16/304 ≤ 2/38 12 (75.0)
Cefepime 4 to ≥ 64 ≥ 64 ≥ 64 ≤ 8 2 (12.5)
Ceftazidime 16 to ≥ 64 ≥ 64 ≥ 64 ≤ 8 0 (0)
Ceftriaxone ≥ 64 ≥ 64 ≥ 64 ≤ 8 0 (0)
Aztreonam ≥ 64 ≥ 64 ≥ 64 ≤ 8 0 (0)
Imipenem ≥ 16 ≥ 16 ≥ 16 ≤ 4 0 (0)
Meropenem ≥ 16 ≥ 16 ≥ 16 ≤ 4 0 (0)
Amikacin 32 to ≥ 64 ≥ 64 ≥ 64 ≤ 16 0 (0)
Gentamicin 8 to ≥ 16 ≥ 16 ≥ 16 ≤ 4 0 (0)
Tobramycin ≥ 16 ≥ 16 ≥ 16 ≤ 4 0 (0)
aData presented as n (%).TMP-SMZ = trimethoprim-sulfamethoxazole; MIC = minimal inhibitory concentration; MIC50 = MIC for 50% of 
isolates; MIC90 = MIC for 90% of isolates.
 503
Chryseobacterium indologenes bacteremia
pyonephrosis, peritonitis, biliary tract infection and 
ventilator-associated pneumonia.3–12 In the hospital envi-
ronment, it is frequently recovered from wet surfaces and 
water systems by virtue of its ability to contaminate and 
persist in fluid-containing apparatuses.12
It is interesting to note that infections caused by 
C. indologenes have been reported mainly from patients 
in Taiwan.3–5,8 However, studies aimed at epidemiological 
surveillance of this organism in various hospitals in 
Taiwan are lacking, and further molecular typing of these 
isolates may help us elucidate the linkage of nosocomial 
infection.
In the literature, most cases of C. indologenes bacter-
emia were detected in hospitalized patients with a severe 
underlying disease, such as malignancies or diabetes mel-
litus, or indwelling devices.3–12 In the present report, the 
majority of underlying diseases were malignancy, diabetes 
mellitus, hypertension, congestive heart failure and 
chronic kidney disease greater than stage 3. The mean age 
of our patients was 66 years, which is older than in a previ-
ous report (50.5 years).5 Male were predominant in our 
study, and this finding is compatible with previous re-
ports.3–12 Twelve of the 16 patients had undergone various 
invasive procedures, such as central venous catheteriza-
tion, urinary catheterization, respiratory assistance or recent 
surgery. It was uncertain as to whether these procedures 
were responsible for bacteremia, and it may suggest that a 
breakdown of infection control techniques was a likely 
cause of infection. As a result, we suggest that C. indologenes 
should be included in the list of pathogens that cause bac-
teremia in immunocompromised hosts, patients with mul-
tiple comorbidities, patients who have undergone various 
invasive procedures and patients who received antibiotics 
over a prolonged period during hospitalization.
In the present study, bacteremia were nosocomially 
acquired and most bacteremia (11/16) developed at least 
10 days after admission. This finding was consistent with 
the literature that most cases of C. indologenes bacteremia 
were due to nosocomial infection.3–12 Hsueh et al found 
nosocomial pneumonia and catheter-related bacteremia 
accounted for most cases.3–5 In this series, primary bacter-
emia was the most common clinical syndrome, account-
ing for 75.0% (12/16) of cases. Although the portal of 
bacteremia was not clearly defined in most patients, it 
may be the result of insufficient microbiological study 
and the retrospective characteristic of this study. Most bac-
teremia developed when the CVC was kept in place and 
catheter-related bacteremia may be underestimated in our 
study. The production of biofilm on foreign materials and 
protease activity may play an important role in the viru-
lence of invasive infections due to C. indologenes.13
The choice of an effective drug for the empirical treat-
ment of infections due to C. indologenes is sometimes dif-
ficult due to the limited data in the literature. In addition, 
the results of susceptibility testing vary when different 
methods are used. However, in vitro susceptibilities deter-
mined by the disk diffusion method showed poor correla-
tion compared with the broth microdilution method, which 
is the preferred methodology.15–17 The MIC breakpoints 
for these organisms have not been established by the 
CLSI.14 Nearly uniform resistance to extended-spectrum 
penicillins, first- and second-generation cephalosporins, 
ceftriaxone, aztreonam, ticarcillin-clavulanate, imipenem, 
meropenem, chloramphenicol, erythromycin and aminogly-
cosides has been reported. Piperacillin-tazobactam, pi-
peracillin, cefoperazone, ceftazidime, cefepime, cefpirome, 
minocycline, rifampicin and trimethoprim-sulfamethoxa-
zole, however, are usually effective.5,15–17 According to the 
results obtained from the SENTRY Antimicrobial Surveil-
lance Program, the newer fluoroquinolones (garenoxacin, 
gatifloxacin and levofloxacin) may represent the most 
appropriate antimicrobial agents to treat C. indologenes 
infections. C. indologenes is usually resistant to imipenem 
due to constitutive production of metallo-β-lactamase.17
In this study, C. indologenes isolates showed various 
susceptibilities to trimethoprim-sulfamethoxazole, levo-
floxacin, ciprofloxacin, piperacillin-tazobactam and 
cefepime. All of the isolates were resistant to other 
β-lactam antibiotics and aminoglycosides, which was in 
accordance with previous reports.3–12,17 However, contrary 
to previous reports,3–12,17 all our isolates were resistant to 
ceftazidime and piperacillin. Cefepime exhibited poor ac-
tivity (12.5% susceptible) against these pathogens, which 
was significantly lower. Among the β-lactams, the most 
active agent overall was piperacillin-tazobactam (50% sus-
ceptible), which showed a much lower susceptibility rate. 
Our analysis showed that trimethoprim-sulfamethoxa-
zole (75% susceptible) was the most potent agent against 
the overall collection of C. indologenes. Fluoroquinolones 
also showed lower activity (ciprofloxacin 43.8% susceptible, 
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levofloxacin 62.5% susceptible) than in the SENTRY 
Antimicrobial Surveillance Program (ciprofloxacin 85% 
susceptible, levofloxacin 100.0% susceptible). However, only 
one report on the treatment of C. indologenes infection with 
newer fluoroquinolones was identified in the literature; 
this case was treated with levofloxacin successfully.6 Fur-
ther research is required to define the role of newer fluo-
roquinolones in the treatment of C. indologenes infections.
Our study revealed an increased rate of resistance in 
C. indologenes to previously potent antibiotics. We have two 
explanations for this phenomenon. First, the age of pa-
tients in our series was older than in previous reports.3–5,17 
Marchaim et al described an increase in the incidence and 
resistance of Gram-negative organisms causing bacter-
emia, concomitant with older patients.18 Second, our anal-
ysis covered the years from 2004 to 2008. The isolates in 
the SENTRY Antimicrobial Surveillance Program were 
collected from 1997 to 2001.18 The isolates of Dr Hsueh’s 
report were from 1992 to 1995.3–5 A 13-year study in a 
hospital demonstrated that significant changes in antimi-
crobial use might have affected antimicrobial resistance in 
certain Gram-negative bacteria from the hospital.19 Hence 
we speculate that the resistant pattern of C. indologenes may 
evolve over time and vary according to different trends of 
antibiotic usage.
In the present study, our patients received antibiotics 
on the basis of the results of the routinely used disk diffu-
sion test, and the appropriate use of antibiotics was 
judged according to MIC testing. Although most of our 
patients did not receive appropriate antibiotics according 
to MIC testing, they recovered from C. indologenes bacter-
emia and only one patient died. This patient had been sub-
ject to prolonged antibiotic usage hospitalization before 
the onset of bacteremia. Multiple indwelling devices were 
kept in place in this patient, possibly implying that the 
production of a biofilm on foreign materials contributed 
to invasive disease and poor outcome. In other literature, 
the mortality attributable to C. indologenes-related infections 
was around 14–17%.3–5 In one study, only one-third of the 
patients infected with C. indologenes received appropriate 
antibiotics according to MIC testing.5 Although our data 
showed a lower rate (18.8%) of appropriate antibiotic usage 
according to MIC testing, our data implied a favorable out-
come of C. indologenes bacteremia. Additionally, our study 
revealed that the outcome of C. indologenes bacteremia was 
not principally influenced by the antibiotic itself. Under-
lying immune defenses and other associated clinical con-
ditions may determine the prognosis of C. indologenes 
bacteremia. The possibility exists that these are cases of 
pseudobacteremia due to contamination by C. indologenes 
during the management of blood cultures. However, this 
possibility is difficult to verify, especially in patients with 
severely debilitating diseases.5
Hsueh et al indicated that indwelling-device-related 
infections caused by C. indologenes did not always require 
removal of devices. In his report, six of seven patients were 
successfully treated with appropriate antibiotics when the 
devices were kept in place.3 Two patients in our study with 
catheter-related bacteremia were successfully treated with-
out appropriate antibiotics against C. indologenes when the 
catheter was removed. Due to the wide range of antibiotic 
resistance and difficulty in determining optimal therapeu-
tic regimens, we suggest that indwelling devices should be 
removed as soon as possible if indwelling device-related 
C. indologenes infection is suspected.
In conclusion, despite the limited case numbers in this 
study, it serves as the largest analysis of clinical and micro-
biological data on C. indologenes bacteremia over the last 
10 years. The pathogenicity and factors for virulence of 
C. indologenes remain unclear, yet our data implied a favora-
ble outcome of bacteremia. The source of bacteremia has not 
yet been clearly identified. The risk factors for C. indologenes 
bacteremia included invasive procedures, immunosuppres-
sion, neutropenia and prolonged use of antibiotics. The 
unique resistance of this organism to multiple antibiotics 
makes it difficult to determine the optimal therapeutic 
option. Newer fluoroquinolones and trimethoprim-
sulfamethoxazole may represent the most appropriate anti-
microbial agents to treat infections caused by this pathogen. 
Further studies aimed at epidemiological surveillance of 
this organism in Taiwan are essential to clarify the linkage 
to nosocomial infections. Furthermore, extensive worldwide 
surveillance programs are vital to the formulation of ap-
propriate antimicrobial therapies and understanding the 
clinical context in which this rare pathogen is isolated.18
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